- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07942038
Myocardial Fibrosis and Deformation Kinetics After the Ross Procedure Using Cardiac MRI
Myocardial Tissue Characterization and Deformation Kinetics Following the Ross Procedure: A Prospective Multiparametric CMR Study
The Ross procedure entails pulmonary autograft replacement of the aortic valve, primarily indicated in pediatric and young adult cohorts presenting with severe aortic valve disease. Despite postoperative preservation of left ventricular ejection fraction (LVEF) on resting transthoracic echocardiography, a subset of recipients exhibits blunted peak oxygen consumption (peak VO2), subclinical electromechanical dyssynchrony, and ventricular arrhythmias.
Chronic severe aortic valve pathology induces distinct myocardial remodeling patterns. Chronic pressure overload (aortic stenosis) triggers concentric cardiomyocyte hypertrophy and diffuse interstitial fibrosis. Chronic volume overload (aortic regurgitation) induces eccentric left ventricular dilatation and extracellular matrix degradation with collagen disarray. Following surgical hemodynamic unloading, left ventricular mass regresses; however, the extent of diffuse interstitial collagen matrix resorption versus pure cardiomyocyte cellular volume regression remains uncharacterized in this demographic.
This prospective longitudinal study employs multiparametric cardiovascular magnetic resonance (CMR) imaging to evaluate myocardial tissue characterization and deformation kinetics in young adults undergoing the Ross procedure. Participants will undergo contrast-enhanced CMR at baseline and at 12 months postoperatively. Quantitative endpoints include native T1 mapping, extracellular volume fraction (ECV), indexed extracellular volume (iECV), and three-dimensional (3D) feature-tracking strain (global longitudinal, circumferential, and radial strain). The primary objective is to correlate the resolution of diffuse microscopic fibrosis with subclinical mechanical recovery, comparing remodeling trajectories between pressure-overloaded and volume-overloaded phenotypes.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
The study population comprises patients presenting with severe primary aortic valve disease-specifically chronic pressure overload (severe aortic stenosis) or chronic volume overload (severe aortic regurgitation)-who are scheduled for an elective full-root Ross procedure (pulmonary autograft replacement of the aortic valve). Patients are recruited prospectively and are evaluated without a history of obstructive coronary artery disease, prior myocardial infarction, primary non-ischemic cardiomyopathy, or systemic connective tissue disorders.
La description
Inclusion Criteria:
- Severe primary aortic valve stenosis, regurgitation, or mixed lesion scheduled for an elective Ross procedure.
- Informed written consent to participate in serial prospective imaging.
Exclusion Criteria:
- Documented coronary artery disease (≥ 50% stenosis or previous coronary revascularization).
- Prior myocardial infarction or primary non-ischemic cardiomyopathy.
- Severe renal impairment (estimated Glomerular Filtration Rate < 30 mL/min/1.73 m²).
- Associated congenital heart disease causing volume overload ex: VSD and PDA.
- Systemic connective tissue disorders (Marfan, Loeys-Dietz, or Ehlers-Danlos syndromes).
- Standard contraindications to contrast-enhanced CMR (incompatible ferromagnetic implants, severe claustrophobia).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Diffuse myocardial fibrosis
Délai: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Quantify the serial longitudinal changes in diffuse myocardial interstitial fibrosis-measured by indexed extracellular volume (iECV, in mL/m²)-from baseline to 12 months postoperatively in young adults undergoing the Ross procedure. |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
|
Diffuse myocardial fibrosis
Délai: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Quantify the serial longitudinal changes in diffuse myocardial interstitial fibrosis-measured by extracellular volume fraction (ECV, in %) |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Subclinical myocardial mechanical recovery
Délai: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Measured by 3D CMR feature-tracking strain analysis by 3D global longitudinal strain (3D-GLS) |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
|
Subclinical myocardial mechanical recovery
Délai: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Measured by 3D CMR feature-tracking strain analysis by 3D global circular strain (3D-GCS) |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
|
Subclinical myocardial mechanical recovery
Délai: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Measured by 3D CMR feature-tracking strain analysis by global radial strain [GRS]. |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
|
Subclinical myocardial mechanical recovery
Délai: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Measured through 3D CMR feature-tracking strain analysis by peak diastolic strain rate. |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- CMR-ROSS
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .